EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab

Cindy X Cai, Akihiko Nishimura, Mary G Bowring, Erik Westlund, Diep Tran, Jia H Ng, Paul Nagy, Michael Cook, Jody-Ann McLeggon, Scott L DuVall, Michael E Matheny, Asieh Golozar und 25 weitere

Ophthalmology Retina · 2024

DOI: 10.1016/j.oret.2024.03.014 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Ophthalmology Retina, 2024. Verfasst von Cindy X Cai und 36 weiteren Autor:innen. Beteiligte Einrichtung: Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: ccai6@jhmi.edu. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Bevacizumab, Ranibizumab, Receptors, Vascular Endothelial Growth Factor. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, NLM NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To characterize the incidence of kidney failure associated with intravitreal anti-VEGF exposure; and compare the risk of kidney failure in patients treated with ranibizumab, aflibercept, or bevacizumab. DESIGN: Retrospective cohort study across 12 databases in the Observational Health Data Sciences and Informatics (OHDSI) network. SUBJECTS: Subjects aged ≥ 18 years with ≥ 3 monthly intravitreal anti-VEGF medications for a blinding disease (diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, or retinal vein occlusion). METHODS: The standardized incidence proportions and rates of kidney failure while on treatment with anti-VEGF were calculated. For each comparison (e.g., aflibercept versus ranibizumab), patients from each group were matched 1:1 using propensity scores. Cox proportional hazards models were used to estimate the risk of kidney failure while on treatment. A random effects meta-analysis was performed to combine each database's hazard ratio (HR) estimate into a single network-wide estimate. MAIN OUTCOME MEASURES: Incidence of kidney failure while on anti-VEGF treatment, and time from cohort entry to kidney failure. RESULTS: Of the 6.1 million patients with blinding diseases, 37 189 who received ranibizumab, 39 447 aflibercept, and 163 611 bevacizumab were included; the total treatment exposure time was 161 724 person-years. The average standardized incidence proportion of kidney failure was 678 per 100 000 persons (range, 0-2389), and incidence rate 742 per 100 000 person-years (range, 0-2661). The meta-analysis HR of kidney failure comparing aflibercept with ranibizumab was 1.01 (95% confidence interval [CI], 0.70-1.47; P = 0.45), ranibizumab with bevacizumab 0.95 (95% CI, 0.68-1.32; P = 0.62), and aflibercept with bevacizumab 0.95 (95% CI, 0.65-1.39; P = 0.60). CONCLUSIONS: There was no substantially different relative risk of kidney failure between those who received ranibizumab, bevacizumab, or aflibercept. Practicing ophthalmologists and nephrologists should be aware of the risk of kidney failure among patients receiving intravitreal anti-VEGF medications and that there is little empirical evidence to preferentially choose among the specific intravitreal anti-VEGF agents. FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsBevacizumabRanibizumabReceptors, Vascular Endothelial Growth FactorRenal InsufficiencyVascular Endothelial Growth Factor AAgedFemaleHumansMaleMiddle AgedBlindnessDiabetic RetinopathyFollow-Up StudiesIncidenceIntravitreal InjectionsMacular EdemaRecombinant Fusion ProteinsRetinal Vein OcclusionRetrospective StudiesRisk Factors

Stichwörter der Autor:innen

Anti-vascular endothelial growth factorBig dataInformaticsKidney failureOHDSIOMOP

Substanzen

afliberceptAngiogenesis InhibitorsBevacizumabRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: ccai6@jhmi.edu.
  • Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Division of Kidney Diseases and Hypertension, Donald and Barbara School of Medicine at Hofstra/Northwell, New York.
  • Department of Biomedical Informatics and Data Science, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.

Förderung

  • NICHD NIH HHS
  • NLM NIH HHS
  • NHLBI NIH HHS
  • NEI NIH HHS
  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NIA NIH HHS
  • NEI

Zitieren

APA

Cai, C. X., Nishimura, A., Bowring, M. G., Westlund, E., Tran, D., Ng, J. H., Nagy, P., Cook, M., McLeggon, J. A., DuVall, S. L., Matheny, M. E., Golozar, A., Ostropolets, A., Minty, E., Desai, P., Bu, F., Toy, B., Hribar, M., Falconer, T., …, & Ryan, P. B. (2024). Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2024.03.014

Vancouver

Cai CX, Nishimura A, Bowring MG, Westlund E, Tran D, Ng JH, et al. Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab. Ophthalmology Retina. 2024. doi:10.1016/j.oret.2024.03.014

BibTeX
@article{Cai2024,
  author = {Cai, Cindy X and Nishimura, Akihiko and Bowring, Mary G and Westlund, Erik and Tran, Diep and Ng, Jia H and Nagy, Paul and Cook, Michael and McLeggon, Jody-Ann and DuVall, Scott L and Matheny, Michael E and Golozar, Asieh and Ostropolets, Anna and Minty, Evan and Desai, Priya and Bu, Fan and Toy, Brian and Hribar, Michelle and Falconer, Thomas and Zhang, Linying and Lawrence-Archer, Laurence and Boland, Michael V and Goetz, Kerry and Hall, Nathan and Shoaibi, Azza and Reps, Jenna and Sena, Anthony G and Blacketer, Clair and Swerdel, Joel and Jhaveri, Kenar D and Lee, Edward and Gilbert, Zachary and Zeger, Scott L and Crews, Deidra C and Suchard, Marc A and Hripcsak, George and Ryan, Patrick B},
  title = {Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab},
  journal = {Ophthalmology Retina},
  year = {2024},
  doi = {10.1016/j.oret.2024.03.014}
}
Kostenlos starten →